851524-90-8

Basic information

• Product Name: 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole
• Synonyms: 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole;3-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole;(3-METHYL-1H-INDOL-5-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 851524-90-8
• Molecular Formula: C₁₅H₂₀BNO₂
• Molecular Weight: 257.1358
• Mol File: 851524-90-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole(851524-90-8)
• EPA Substance Registry System: 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole(851524-90-8)

Safety Data

• Hazardous Substances Data: 851524-90-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole is used as a chemical intermediate in organic synthesis for the preparation of various compounds. Its boron-containing moiety allows it to participate in Suzuki-Miyaura coupling reactions, which are widely used in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole is used as a starting material in the development of new drugs due to its potential medicinal properties. Its unique structure and reactivity make it a valuable compound for designing and synthesizing novel pharmaceutical agents.
Used in Drug Development:
In the pharmaceutical industry, 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole is used as a key component in the synthesis of drug candidates. Its versatility in chemical reactions enables the creation of diverse drug molecules with potential therapeutic applications.
Overall, 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole has important applications in both synthetic chemistry and pharmaceutical research, making it a valuable compound for the development of new drugs and the advancement of chemical synthesis techniques.

Upstream product

• 10075-48-6 5-bromo-3-methyl-1H-indole 
• 73183-34-3 bis(pinacol)diborane 
• 10075-50-0 5-bromo-1H-indole 
• 1000343-13-4 5-bromo-6-methyl-1H-indole 
• 877-03-2 5-bromo-1H-indole-3-carboxaldehyde 

Downstream Products

• 1300584-97-7 2-(1-(4-Amino-3-(3-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 

Relevant articles and documents

4-aminopyrazolo [3, 4-d] pyrimidine derivative and application thereof

The invention discloses a 4-aminopyrazolo [3, 4-d] pyrimidine derivative and application thereof, the structure of the derivative is as shown in formula I, A is an aromatic ring group or an aromatic heterocyclic group; L is fat alkane; Cyclic is of an N-containing heterocyclic structure; Q is carbonyl or sulfonyl; R is alkane, aryl or heteroaryl. A novel 4-aminopyrazolo [3, 4-d] pyrimidine derivative is synthesized and screened, the activity of an ALK5 receptor can be inhibited in a dose-dependent mode, and the derivative or a solvate and a medicinal salt of the derivative can be applied to preparation of drugs for treating and/or preventing cancers.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES

A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds

FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Fused bicycloheterocycle substituted quinuclidine derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Fused bicycloheterocycle substituted quinuclidine derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Fused bicycloheterocycle substituted quinuclidine derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.